Palvella Therapeutics (NASDAQ:PVLA) Shares Down 7.8% Following Insider Selling

by · The Cerbat Gem

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) shares fell 7.8% during mid-day trading on Friday following insider selling activity. The company traded as low as $84.66 and last traded at $84.91. 136,058 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 203,700 shares. The stock had previously closed at $92.08.

Specifically, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Mizuho initiated coverage on Palvella Therapeutics in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $205.00 target price for the company. Cantor Fitzgerald upped their price objective on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Truist Financial lifted their target price on Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, HC Wainwright set a $200.00 price target on Palvella Therapeutics and gave the company a “buy” rating in a research report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $158.69.

Read Our Latest Stock Analysis on PVLA

Palvella Therapeutics Price Performance

The stock has a market capitalization of $1.01 billion, a P/E ratio of -32.43 and a beta of -0.16. The stock has a 50 day moving average price of $97.37 and a 200-day moving average price of $70.70.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Research analysts predict that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PVLA. Archer Investment Corp purchased a new stake in Palvella Therapeutics in the third quarter worth about $28,000. Russell Investments Group Ltd. purchased a new position in shares of Palvella Therapeutics in the third quarter worth $36,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Palvella Therapeutics during the second quarter valued at $37,000. JPMorgan Chase & Co. lifted its holdings in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Palvella Therapeutics in the 2nd quarter worth about $85,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

See Also